About 6 results found for searched term "B-Raf IN 15" (0.18 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M42156 | B-Raf IN 15 | Raf |
| B-Raf IN 15 is a BRAF inhibitor. | ||
| M3026 | Sorafenib (BAY 43-9006) | Raf |
| BAY 43-9006 | ||
| Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. Sorafenib is a multikinase inhibitor with IC50 values of 15 nM, 20 nM, 57 nM and 58 nM for VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib is a ferroptosis activator. | ||
| M14181 | LY3009120 | Raf |
| DP-4978 | ||
| LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAFV600E, BRAFWT and CRAFWT with IC50s of 5.8, 9.1 and 15 nM, respectively. | ||
| M30907 | B-Raf IN 11 | Raf |
| B-Raf IN 11 (ZINC72115182) is a selective B-RafV600E inhibitor (IC50=76 nM), shows selectivity for B-RafV600E over B-RafWT with selectivity of 3.1-fold. B-Raf IN 11 can be used in colorectal cancer research[1] | ||
| M54707 | INX-315 | CDK |
| INX-315 is an orally potent and selective CDK2 inhibitor that induces cell cycle arrest in G1 phase. INX-315 also induces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in a xenograft mouse model.INX-315 can be used in cancer-related studies. | ||
| M57279 | BC-1215 | Ligand for E3 Ligase |
| BC1215 | ||
| BC-1215 is a novel inhibitor of F-box protein 3 (Fbxo3) activity. BC-1215 works by antagonizing of Fbxo3 on TRAF cytokine signaling and exhibits a low IC50 in vitro. BC-1215 relieves allodynia by preventing ubiquitination-dependent Fbxl2/TRAF2/TNIK/pGluR1 signaling. BC-1215 exerted robust therapeutic effects in cytokine-driven inflammation, including pseudomona-induced lung injury and cecum ligation/punctured-induced sepsis, by targeting Fbxo3/Fbxl2/TRAF-mediated cytokine release. BC-1215 can be used for the research of inflammation. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
